ResMed Inc. RMD NYSE

ResMed Inc. (RMD) generated $1.75B in operating cash flow for fiscal year 2025. After capital expenditures of $89.87M, free cash flow was $1.66B.

Free cash flow margin was 32.3% of revenue. Cash conversion ratio was 1.25x, indicating earnings are backed by cash.

The company returned $310.88M in dividends and $300.03M in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (80/100, Pass) — $1.66B (32.3% FCF margin) supports a durable competitive advantage
• INCOME (85/100) — Cash conversion ratio was 1.25x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 78/100 with 5/7 criteria passed.